Allegro Gives Phase II News on Luminate

[creativ_media type=”vimeo” url=”″]

Vicken Karageozian, MD, Co-Founder and CTO of Allegro Opthalmics LLC, updated the OIS audience on the clinical trial progress of Luminate, a first-in-class integrin peptide therapy that treats vitreo-retinal diseases by utilizing two mechanisms of action, anti-angiogenesis and vitreolysis. The company just initiated a Phase II study of the drug as a treatment of diabetic macular edema (DME). The company is close to reporting a data lock in a Phase II trial against vitreomacular traction (VMT).



Vicken Karageozian, MD

Dr. Karageozian is the CTO and Co-Founder of Allegro Ophthalmics and has 22+ years of experience in ophthalmic drug development at Allergan, ISTA Pharmaceuticals, and Vitreoretinal Technologies.

View Full Profile